Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial

Journal of the National Cancer Institute

Volumn 94, Issue 14, 2002, Pages 1054-1065

  Castiglione Gertsch, Monica ^a   Price, Karen N ^b   Goldhirsch, Aron ^c,d   Coates, Alan S ^e   Colleoni, Marco ^c   Nasi, M Laura ^f   Bernhard, Jürg ^g   Zahrieh, David ^b   Bonetti, Marco ^b   Gelber, Richard D ^b   Egli, G ^h   Rabaglio, M ^h   Maibach, R ^h   Gerber, M Iannino ^h   Hiltbrunner, A ^h   Peterson, H ⁱ   Zelen, M ⁱ   Gelber, S ⁱ   O'Neill, A ⁱ   Litman, H ⁱ   Hinkle, R ^b   Isley, M ^b   Blacher, L ^b   Lippert, S ^b   Celano, J ^b   Guster Son, B ^j   Bettelheim, R ^j   Reed, R ^j   Mallon, E ^j   Hurny Ch ^k   Gusset, H ^k   Mathys, N ^k   Cliffe, B ^k   Crivellari, D ^l   Mon Fardini, S ^l   Galligioni, E ^l   Magri, M D ^l   Veronesi, A ^l   Buonadonna, A ^l   Massarut, S ^l   Rossi, C ^l   Candiani, E ^l   Carbone, A ^l   Volpe, R ^l   Roncadin, M ^l   Arcicasa, M ^l   Coran, F ^l   Morassut, S ^l   Simoncini, E ^m   Marini, G ^m   Marpicati, P ^m   Braga, M ^m   Grigolato, P ^m   Lucini, L ^m   Foladore, S ⁿ   Foghin, L ⁿ   Pamich, G ⁿ   Bianchi, C ⁿ   Marino, B ⁿ   Murgia, A ⁿ   Milan, V ⁿ   Martinelli, G ^c   Orlando, L ^c   Nole F ^c   Luini, A ^c   Orecchia, R ^c   Viale, G ^c,j   Peccatori, F ^c   de Braud, F ^c   Costa, A ^c   Zurrida, S ^c   Veronesi, P ^c   Sacchini, V ^c   Galimberti, V ^c   Intra, M ^c   Veronesi, U ^c   Ravaioli, A ^o   Tassinari, D ^o   Oliverio, G ^o   Barbanti, F ^o   Rinaldi, P ^o   Gianni, L ^o   Drudi, G ^o   Antimi, M ^p   Minelli, M ^p   Bellini, V ^p   Porzio, R ^p   Pernazza, E ^p   Santeusanio, G ^p   Spagnoli, L G ^p   Magazu, M ^q   Fosser, V ^q   Morandi, P ^q   Scalco, G ^q   Balli, M ^q   Gion, M ^q   Meli, S ^q   Torsello, G ^q   Fey, M F ^a   Castiglione Gertsch, M ^a   Dreher, E ^a   Schneider, H ^a   Aebi, S ^a   Ludin, J ^a   Beck, G ^a   Haenel, A ^a   Luthi J M ^a   Altermatt, H J ^a   Nandedkar, M ^a   Buser, K ^a   Senn, H J ^r   Thurlimann B ^r   Oehlschlegel, Ch ^r   Ries, G ^r   Topfer M ^r   Lorenz, U ^r   Schiltknecht, O ^r   Spati B ^r   Ehrsam, A ^r   Bamert, M ^r   Jungi, W F ^r   Cavalli, F ^d   Pagani, O ^d   Neuenschwander, H ^d   Bronz, L ^d   Sessa, C ^d   Ghielmini, M ^d   Rusca, T ^d   Rey, P ^d   Bernier, J ^d   Pedrinis, E ^d   Gyr, T ^d   Leidi, L ^d   Pastorelli, G ^d   Caccia, G ^d   Goldhirsch, A ^c,d   Herrmann, R ^s   Rochlitz, C F ^s   Harder, J F ^s   Kochli O ^s   Eppenberger, U ^s   Torhorst, J ^s   Piguet, D ^t   Siegenthaler, P ^t   Barrelet, V ^t   Baumann, R P ^t   Pestalozzi, B ^u   Sauter, C ^u   Fink, D ^u   Fehr, M ^u   Haller, U ^u   Metzger, U ^u   Huguenin, P ^u   Caduff, R ^u   Perey, L ^v   Leyvraz, S ^v   Anani, P ^v   Gomez, F ^v   Wellman, D ^v   Chapuis, G ^v   De Grandi, P ^v   Reymond, P ^v   Gillet, M ^v   Delaloye, J F ^v   Alberto, P ^w   Bonnefoi, H ^w   Schafer P ^w   Krauer, F ^w   Forni, M ^w   Aapro, M ^w   Egeli, R ^w   Megevand, R ^w   Jacot Des Combes, E ^w   Schindler, A ^w   Borisch, B ^w   Diebold, S ^w   Egli, F ^x   Forrer, P ^x   Willi, A ^x   Steiner, R ^x   Allemann, J ^x   Ruedi T ^x   Leutenegger, A ^x   Dalla Torre, U ^x   Forbes, J F ^y,ad   Lindsay, D ^y   Wilson, A ^y   Dhillon, H ^e   Collins, J ^z   Snyder, R ^z   Basser, R ^z   Burns, W I ^z   Chipman, M ^z   Chirgwin, J ^z   Drummond, R ^z   Francis, P ^z   Green, M ^z   Gregory, P ^z   Hart, S ^z   Henderson, M ^z   Kitchen, P ^z   McLennan, R ^z   Murphy, C ^z   Neil, S ^z   Pitcher, M ^z   Richardson, G ^z   Rodger, A ^z   Schwarz, M ^z   Mitchell, P ^z   Joseph, D ^z,ag   Griffiths, J ^z   Stanley, R ^z   Jeal, P ^z   Olver, I ^z   Zalcberg, J ^z   Lindeman, G ^z   Finkelde, D ^z   Goss, G ^z   Steele, M ^z   Mann, B ^z   Read, A ^z   Russell, I ^z   Stewart, J ^z,ad   Underhill, C ^z   Reading, D ^z   Kay, R G ^aa   Harvey, V J ^aa   Benjamin, C S ^aa   Thompson, P ^aa   Bierre, A ^aa   Miller, M ^aa   Hochstein, B ^aa   Lethaby, A ^aa   Webber, J ^aa   Porter, D ^aa   Malden, T ^ab   Jackson, D ^ad   Gourlay, R ^ad   Bishop, J ^ad   Cox, S ^ad   Ackland, S ^ad   Bonaventura, A ^ad   Hamilton, C ^ad   Denham, J ^ad   O'Brien, P ^ad   Back, M ^ad   Brae, S ^ad   Muragasu, ^ad   Lewis, C ^ae   Olver, I N ^af   Keefe, D ^af   Brown, M ^af   Gill, P G ^af   Taylor, A ^af   Yeoh, E ^af   Abdi, E ^z,af   Cleary, J ^af   Parnis, F ^af   Byrne, M ^ag   Van Hazel, G ^ac,ag   Dewar, J ^ag   Buck, M ^ag   Sterrett, G ^ag   Ingram, D ^ag   Hastrich, D ^ag   Cameron, F ^ag   Tattersall, M H N ^e   Coates, A S ^e   Niesche, F ^e   West, R ^e   Renwick, S ^e   Donovan, J ^e   Duval, P ^e   Simes, Robert John ^e   Ng, A ^e   Glenn, D ^e   North, R A ^e   Beith, J ^e   O'Connor, R G ^e   Rice, M ^e   Stevens, G ^e   Grassby, J ^e   Pendlebury, S ^e   McLeod, C ^e   Boyer, M ^e   Sullivan, A ^e   Hobbs, J ^e   Lind, D ^e   Kennedy, I ^ah   Round, G ^ah   Long, J ^ah   Rudenstam, C M ^ai   Wallgren, A ^ai   Ottosson Lonn S ^ai   Hultborn, R ^ai   Colldahl Jaderstrom G ^ai   Cahlin, E ^ai   Mattsson, J ^ai   Holmberg, S B ^ai   Ivarsson, L ^ai   Ruusvik, O ^ai   Niklasson, L G ^ai   Dahlin, S ^ai   Karlsson, G ^ai   Lindberg, B ^ai   Sundback A ^ai   Bergegardh S ^ai   Salander, H ^ai   Andersson, C ^ai   Heideman, M ^ai   Hessman, Y ^ai   Nelzen O ^ai   Claes, G ^ai   Ramhult, T ^ai   Svensson, J H ^ai   Liedberg, P ^ai   Suurkula M ^ai   Persson, S ^ai   Dent, D M ^aj   Gudgeon, A ^aj   Murray, E ^aj   Werner, I D ^aj   Steynor, P ^aj   Toop, J ^aj   McEvoy, E ^aj   Vorobiof, D ^ak   Chasen, M ^ak   Fotheringham, G ^ak   de Muelenaere, G ^ak   Skudowitz, B ^ak   Mohammed, C ^ak   Rosengarten, A ^ak   Lindtner, J ^al   Erzen, D ^al   Majdic, E ^al   Stabuc, B ^al   Plesnicar, A ^al   Golouh, R ^al   Lamovec, J ^al   Jancar, J ^al   Vrhoved, I ^al   Kramberger, M ^al   Cortes Funes H ^am   Mendiola, D ^am   Hornedo, J ^am   Colomer, R ^am   Vigo, F Cruz ^am   Miranda, P ^am   Sierra, A ^am   Martinez Tello, F ^am   Garzon, A ^am   Alonso, S ^am   Ferrero, A ^am   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e UNIVERSITY OF SYDNEY   (Australia)

^f IBCSG Coordinating Center   (Switzerland)

^g IBCSG Quality of Life Office   (Switzerland)

^h Intl Breast Cancer Stud Grp   (Switzerland)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j Pathology Office   (Australia)

^k Quality of Life Office   (Australia)

^l CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^m SPEDALI CIVILI   (Italy)

ⁿ Ospedale Civile di Gorizia   (Italy)

^o Ospedale Infermi   (Italy)

^p S EUGENIO HOSPITAL   (Italy)

^q SAN BORTOLO HOSPITAL   (Italy)

^r CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^s UNIVERSITY HOSPITAL BASEL   (Switzerland)

^t Hopital Pourtales Neuchatelois   (Switzerland)

^u KANTONSSPITAL   (Switzerland)

^v LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^w GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^x KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^y UNIVERSITY OF NEWCASTLE   (Australia)

^z CANCER EPIDEMIOLOGY CENTRE   (Australia)

^aa Auckland Breast Cancer Study Group   (New Zealand)

^ab FLINDERS MEDICAL CENTRE   (Australia)

^ac Mount Hospital   (Australia)

^ad NEWCASTLE MATER HOSPITAL   (Australia)

^ae Prince os Wales Private Hospital   (Australia)

^af ROYAL ADELAIDE HOSPITAL   (Australia)

^ag SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^ah WAIKATO HOSPITAL   (New Zealand)

^ai West Swedish Breast Cancer Study Group   (Sweden)

^aj UNIVERSITY OF CAPE TOWN   (South Africa)

^ak Sandton Oncology Centre   (South Africa)

^al INSTITUTE OF ONCOLOGY   (Slovenia)

^am Madrid Breast Cancer Group   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART INFARCTION; HORMONE RELEASE; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE REGRESSION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UTERUS SARCOMA;

EID: 0037125429     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use CD-ROM (1973–1996), National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, released April 1999, based on the August 1998 submission.
2. Fisher B, Costantino J, Redmond E, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479–84.
3. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988;57:608–11.
4. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Natl Cancer Inst Monogr 1992;11:117–20.
5. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451–67.
6. Ludwig Breast Cancer Study Group. Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984;1:1256–60.
7. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997;15:1385–94.
8. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994;12:2078–85.
9. ® and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100). SWOG, ECOG, CALGB, NCCTG, and NCI-Canada. Proc ASCO 1997;16:128a.
10. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005–18.
11. Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999;17:1988–98.
12. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930–42.
13. th ed. Berlin (Germany): Springer-Verlag; 1987.
14. Davis BW, Zava DT, Locher GW, Goldhirsch A, Hartmann WH. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984;20:375–82.
15. Berger U, Wilson P, McClelland RA, Davidson J, Coombes RC. Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer. Hum Pathol 1987; 18:1263–7.
16. Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, et al. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys 1996;35: 649–59.
17. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thurlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. International Breast Cancer Study Group. J Clin Oncol 2000;18:1412–22.
18. Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 1996;347:1279–84.
19. Bernhard J, Hurny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. International Breast Cancer Study Group. Ann Oncol 1997;8:825–35.
20. Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 2001;84:1156–65.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.
22. Greenwood M. The natural duration of cancer. London: HM Stationary Office, 1926.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.
24. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc 1972;34:187–220.
25. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19:2595–609.
26. Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Coates AS. Features that predict responsiveness to chemotherapy and endocrine therapies. International Breast Cancer Study Group (IBCSG). The Breast 2001;10(Suppl 3):147–57.
27. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986;58:2662–70.
28. Fisher B, Dignam J, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996;14:1982–92.
29. Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis—an intergroup study. J Clin Oncol 1998; 16:3486–92.
30. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, et al. The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group. Isr J Med Sci 1995;31:144–54.
31. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491–6.
32. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001;19:4141–9.
33. Colleoni M, Gelber RD, Gelber S, Castiglione-Gertsch, Coates AS, Goldhirsch A. How to improve timing and duration of adjuvant chemotherapy. The Breast 2001;10(Suppl 3):101–5.
34. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998;90:1601–8.
35. Colleoni M, Coates A, Pagani O, Goldhirsch A. Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? Cancer Treat Rev 1998;24:15–26.
36. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89:1673–82.
37. Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of The International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632–40.
38. Klijn JG, Blamey RW, Boccardo F. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343–53.
39. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996;14:1885–94.
40. Sauerbrei W, Bastert G, Bojar H, Beyerle C, Neumann RL, Schmoor C, et al. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years’ follow-up. German Breast Cancer Study Group. J Clin Oncol 2000;18:94–101.
41. Maass H. 3 versus 6 cycles of CMF in breast cancer patients with 1 to 9 positive nodes: results of the German Adjuvant Breast Cancer Group (GABG) III trial. Proc ASCO 2000;19:73a.
42. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002;86:1705–14.
43. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial Int 0102. Proc ASCO 1998;17:1a.
44. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997–2008.
45. Gelber RD, Goldhirsch A. Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct. Ann Oncol 1991;2:461–8.
46. Gelber RD, Coates AS, Goldhirsch A. Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses. Ann Oncol 1992;3: 683–91.
47. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. J Clin Oncol 1993;11:580–5.
48. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001;358:277–86.
49. Coates AS, Gelber RD, Goldhirsch A. Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 1998;352: 1783–4.
50. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474–81.
51. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001;19:3817–27.